Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.75p
   
  • Change Today:
      0.000p
  • 52 Week High: 4.05
  • 52 Week Low: 0.70
  • Currency: UK Pounds
  • Shares Issued: 427.35m
  • Volume: 14,825
  • Market Cap: £3.21m

Latest ShareCast News

Evgen upbeat on start of glioblastoma research project

By Josh White

Date: Thursday 26 Oct 2023

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Evgen Pharma doses first volunteers in SFX-01 trial

By Josh White

Date: Wednesday 16 Nov 2022

(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it announced on Wednesday.

Evgen starts recruiting volunteers for trial of lead asset

By Josh White

Date: Wednesday 12 Oct 2022

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the start of recruitment for the pharmacokinetic and pharmacodynamic trial in healthy volunteers, and the decision to commence an investigator-sponsored clinical study for the glioblastoma programme on Wednesday.

Evgen agrees fresh licensing deal with Spanish i... 18-Jan-2022 ShareCast
Evgen pleased with preclinical data on SFX-01 13-Jul-2021 ShareCast
Evgen 'surprised and disappointed' by findings i... 09-Jul-2021 ShareCast
Evgen upbeat on new data on potential breast can... 14-Jun-2021 ShareCast
Evgen appoints Helen Kuhlman as chief business o... 22-Mar-2021 ShareCast
Evgen Covid-19 trial given all-clear on safety a... 11-Mar-2021 ShareCast
Evgen makes progress with recruitment in 'STAR' ... 17-Feb-2021 ShareCast
Evgen announces positive preclinical data for SF... 22-Jan-2021 ShareCast
Evgen reports 'highly positive' data from SFX-01... 21-Jan-2021 ShareCast
Evgen Pharma makes progress with 'STAR' trial re... 19-Jan-2021 ShareCast
Evgen Pharma performs in line with forecasts in ... 10-Dec-2020 ShareCast
Evgen doses first patients in 'STAR' respiratory... 23-Nov-2020 ShareCast
Evgen gets full approval for SFX-01 trial in Cov... 23-Oct-2020 ShareCast
Evgen Pharma licences technology to Juvenescence 15-Sep-2020 ShareCast
Evgen's 'SFX-01' to be tested with Covid-19 pati... 17-Jun-2020 ShareCast
Losses widen as Evgen Pharma develops SFX-01 15-Jun-2020 ShareCast
Evgen Pharma in talks about funding for Covid-19... 15-May-2020 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.75p
Change Today 0.000p
% Change 0.00 %
52 Week High 4.05
52 Week Low 0.70
Volume 14,825
Shares Issued 427.35m
Market Cap £3.21m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
93.55% below the market average93.55% below the market average93.55% below the market average93.55% below the market average93.55% below the market average
78.18% below the sector average78.18% below the sector average78.18% below the sector average78.18% below the sector average78.18% below the sector average
Income Not Available
Growth Not Available

Theracryf Dividends

No dividends found

Trades for 03-May-2024

Time Volume / Share Price
16:10 604 @ 0.75p
15:39 1,764 @ 0.79p
11:59 12,457 @ 0.70p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page